A landmark study from Scotland has shown that bivalent HPV vaccine confers significant protection against cervical epithelial dyskaryosis and dysplasia, both precursors of invasive cervical cancer. This study reports statistically significant reductions in all grades of CIN, equating to vaccine effectiveness estimates of 80% or greater after routine immunisation of girls at age 12-13 years.